Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102 KOL s and m anagement to p resent on Thursday, October 6 th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc.

REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers today announced

- Updated interim results from Part A of RINGSIDE show first confirmed partial response (PR) achieved at week 16 and 3 additional unconfirmed PRs over the follow-up period - - Consistent early tumor shrinkage with measures deepening over time - - AL102 was well tolerated at all doses evaluated - -

Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study REHOVOT, Israel and WILMINGTON, Del., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule

Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data set from RINGSIDE to be presented at ESMO REHOVOT, Israel and WILMINGTON, Del., Aug.

- Tumor shrink ing observed in substantially all patients who were evaluable at 16 weeks - - Favorable safety results observed : AL102 was well tolerated - - Additional data to be submitted for presen t ation at a medical conference in 2H 2022 - REHOVOT, Israel & WILMINGTON, Del., July 05, 2022

-- Presentation at ASCO features updated results from Phase 2 ACCURACY study -- -- AL101 demonstrated anti-tumor activity by achieving an overall disease control rate of 69% -- -- Patients achieving partial responses had higher progression-free survival -- REHOVOT, Israel & WILMINGTON, Del., June

REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in

Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for

REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in